Cargando…

Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy

BACKGROUND: Erdheim–Chester disease (ECD), a rare inflammatory myeloid neoplasm, is known to be fundamentally reliant on the constitutive activation of the MAPK signaling pathway in the majority of patients. Consequently, inhibition of the V600E-mutant BRAF kinase has proven to be a safe and efficac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mazor, Roei D, Weissman, Ran, Luckman, Judith, Domachevsky, Liran, Diamond, Eli L, Abdel-Wahab, Omar, Shapira, Shirley, Hershkovitz-Rokah, Oshrat, Groshar, David, Shpilberg, Ofer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212923/ https://www.ncbi.nlm.nih.gov/pubmed/32642685 http://dx.doi.org/10.1093/noajnl/vdaa024

Ejemplares similares

The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim–Chester Disease
por: Weissman, Ran, et al.
Publicado: (2020)

Real‐World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim‐Chester Disease
por: Saunders, Ila M., et al.
Publicado: (2019)

Erdheim-Chester Disease: a comprehensive review of the literature
por: Mazor, Roei D, et al.
Publicado: (2013)

Vemurafenib for BRAF V600‐mutant Erdheim–Chester disease presenting with bilateral orbital involvement
por: Wang, Xiaomeng, et al.
Publicado: (2023)

NAD(P)H Quinone Oxidoreductase Protects TAp63γ from Proteasomal Degradation and Regulates TAp63γ-Dependent Growth Arrest
por: Hershkovitz Rokah, Oshrat, et al.
Publicado: (2010)

Case report of a patient with Erdheim-Chester disease presenting with neuro-endocrine symptoms and negative for BRAF mutation
por: Lu, Liuze, et al.
Publicado: (2023)

Erdheim-Chester Disease With BRAF V600E Mutation and Central Diabetes Insipidus Successfully Treated With Glucocorticoid
por: Imaizumi, Toshinori, et al.
Publicado: (2023)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease
por: Janku, Filip, et al.
Publicado: (2014)

Erdheim–Chester disease presenting as acute ischaemic cardiomyopathy and aortitis in a BRAF V600E-negative patient
por: Nicolas, Anthony J, et al.
Publicado: (2021)

A case of Erdheim–Chester disease with the BRAF V600E mutation diagnosed via endoscopic sinus surgery
por: Matsuhisa, Takaharu, et al.
Publicado: (2023)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition
por: Campos, Maira P., et al.
Publicado: (2018)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Non-Coding RNAs in Normal B-Cell Development and in Mantle Cell Lymphoma: From Molecular Mechanism to Biomarker and Therapeutic Agent Potential
por: Kersy, Olga, et al.
Publicado: (2021)

Three cases of BRAF mutation negative Erdheim-Chester disease with a challenging distinction from IgG4-related disease
por: Spoerl, David, et al.
Publicado: (2021)

Targeted therapy monitoring of BRAF-V600-mutant Erdheim-Chester disease by fast quantitative whole-body bone CZT-tomoscintigraphies
por: Melki, Saifeddine, et al.
Publicado: (2023)

Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations
por: Prabhakaran, Nitya, et al.
Publicado: (2023)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
por: Del Curatolo, Anais, et al.
Publicado: (2018)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histiocytosis and Erdheim–Chester disease
por: Váradi, Zsófia, et al.
Publicado: (2017)

Indolent renal involvement with BRAF(V600E) mutation: Erdheim‐Chester, a rare disease with a wide spectrum of clinical manifestations
por: Vanhomwegen, Charlotte, et al.
Publicado: (2021)

维莫非尼治疗BRAF(V600E)突变型Erdheim-Chester病的疗效与安全性分析
Publicado: (2021)

Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing BRAF(V600E) -Mutated Erdheim–Chester Disease: A Case Report
por: Razanamahery, Jérôme, et al.
Publicado: (2022)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis
por: Weissman, Ran, et al.
Publicado: (2021)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
por: Tholander, Bengt, et al.
Publicado: (2020)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
por: Saijo, Ken, et al.
Publicado: (2022)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
por: Garutti, Mattia, et al.
Publicado: (2022)

Network analysis of microRNAs, genes and their regulation in diffuse and follicular B-cell lymphomas
por: Hershkovitz-Rokah, Oshrat, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_s41i195jj576souc2bifidrngu